The role of chymase in vascular proliferation

Drug News and Perspectives

Volumn 15, Issue 5, 2002, Pages 278-282

  Takai, Shinji ^a   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 (5 FORMYLAMINO 6 OXO 2 PHENYL 1,6 DIHYDROPYRIMIDIN 1 YL) N [(3,4 DIOXO 1 PHENYL 7 (2 PYRIDYLOXY)] 2 HEPTYL]ACETAMIDE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN I; CHYMASE; CHYMASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE; N [1 BENZYL 2,3 DIOXO 6 (2 PYRIDYLOXY)HEXYL] 2 (5 FORMYLAMINO 1,6 DIHYDRO 6 OXO 2 PHENYL 1 PYRIMIDINYL)ACETAMIDE; RENIN; TRANILAST; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL MODEL; ARTERY INTIMA PROLIFERATION; BALLOON CATHETER; BLOOD VESSEL INJURY; CELL PROLIFERATION; DOG; ENZYME ACTIVATION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; MAST CELL; PLASMA RENIN ACTIVITY; REVIEW; VASCULAR TISSUE; VEIN GRAFT;

EID: 0036071832     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2002.15.5.840040     Document Type: Review

References (45)

1. Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases
2. Cilazapril inhibits wall thickening of vein bypass graft in the rat
3. Effects of angiotensin converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in the baboon
4. Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury
5. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty?
6. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: Final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril
7. Different distribution of two types of angiotensin II-generating enzymes in the aortic wall
8. Functional role of chymase in angiotensin II formation in human vascular tissue
9. Chymase-dependent angiotensin II formation in human vascular tissue
10. Different angiotensin II-forming pathways in human and rat vascular tissues
11. Characterization of chymase from human vascular tissues
12. Induction of chymase that forms angiotensin II in the monkey atherosclerotic aorta
13. Angiotensin II generation by mast cell alpha- and beta-chymases
14. Purification and characterization of angiotensin II-generating chymase from hamster cheek pouch
15. Valsartan for prevention of restenosis after stenting of type B2/C lesions: The VAL-PREST trial
16. Coronary arterial bypass grafts
17. Aorta-to-coronary-artery vein bypass graft for coronary artery occlusive disease
18. Postoperative changes in autologous vein grafts
19. Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts
20. Vein graft disease: The clinical impact of stenoses in saphenous vein bypass grafts to coronary arteries
21. Differential action of angiotensin II and activity of angiotensin-converting enzyme in human bypass grafts
22. Chymase-dependent angiotensin II formation in the saphenous vein versus the internal thoracic artery
23. Inhibition of chymase reduces vascular proliferation in dog grafted veins
24. Significance of chymase-dependent angiotensin II-forming pathway in the development of vascular proliferation
25. Angiotensin II receptor antagonist, L-158,809, prevents intimal hyperplasia in dog grafted veins
26. Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein
27. Lengthy suppression of vascular proliferation by a chymase inhibitor in dog grafted veins
28. Healing basis and surgical techniques for complete revascularization of the left ventricle using only the internal mammary arteries
29. Angiotensin II type 1 receptor blockade prevents up-regulation of angiotensin II type 1A receptors in rat injured artery
30. Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed Cynomolgus monkeys
31. Human mast cells express stem cell factor
32. Effect of an angiotensin II receptor antagonist, candesartan cilexetil, on canine intima hyperplasia after balloon injury
33. Angiotensin II type 1 receptor antagonist, TCV-116, prevents neointima formation in injured arteries in the dog
34. Tranilast suppresses vascular chymase expression and neointima formation in balloon-injured dog carotid artery
35. Effects of novel chymase inhibitor, NK3201, on canine intimal hyperplasia after balloon injury
36. Tranilast suppresses intimal hyperplasia in the balloon injury model and cuff treatment model in rabbits
37. Inhibition of neointima formation by tranilast in pig coronary arteries after balloon angioplasty and stent implantation
38. Application of in vivo and ex vivo magnetic resonance imaging for evaluation of tranilast on neointima formation following balloon angioplasty of the rat carotid artery
39. Impact of tranilast on restenosis after coronary angioplasty: Tranilast restenosis following angioplasty Trial (TREAT)
40. The impact of tranilast on restenosis after coronary angioplasty: The Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2)
41. The inhibition mechanism of histamine release by N-(3,4-dimethoxycinnamoyl) anthranilic acid
42. Association between the expression of mast cell chymase and intraperitoneal adhesion formation in mice
43. Mast cell mediators with emphasis on intestinal mast cells
44. Mast cells are critical for the production of leukotrienes responsible for neutrophils recruitment in immune complex-induced peritonitis in mice
45. Eotaxin-induced eosinophil migration in the peritoneal cavity of ovalbumin-sensitized mice: Mechanism of action